Compare Supplements

Side-by-side comparison of 2 supplements

Efp4.3

Efpeglenatide

Limited safety

Lir7.5

Liraglutide

Limited safety

Evidence

Mostly mechanism / observational

Evidence Score4.3/10

Studies: 7

Meta-analyses: 2

Mostly mechanism / observational

Evidence Score7.5/10

Studies: 13

Meta-analyses: 3

Dosage & timing

Dosage:

INVESTIGATIONAL — NO approved or consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration; it is an unapproved, unmarketed investigational drug.

Best Time:

Any time

Can take on empty stomach

Form:

Once-weekly subcutaneous injection (investigational only)

Dosage:

Prescription-only, clinician-titrated, subcutaneous once daily. Diabetes (Victoza): escalate 0.6 → 1.2 → 1.8 mg/day. Weight management (Saxenda): escalate weekly to 3.0 mg/day. DO NOT self-dose.

Best Time:

Any time

Can take on empty stomach

Form:

Subcutaneous once-daily injection (Victoza for diabetes, Saxenda for weight)

What you'll notice

❤️ Reduced major cardiovascular events (MACE)positive

Over ~1.8 years (trial follow-up)

🫘 Reduced kidney-outcome eventspositive

Over ~1.8 years

🩸 Improved glycemic controlpositive

Weeks to months

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Moderate weight losspositive

Months (titrated over weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

Safety

Limited safety

Contraindications:

Not a dietary supplement and not an approved/marketed drug — investigational; do not self-source grey-market vials
Personal/family history of medullary thyroid carcinoma or MEN 2 (expected GLP-1-class thyroid C-cell warning)
History of pancreatitis

Drug Interactions:

Oral medications (delayed gastric emptying)
Insulin / insulin secretagogues (sulfonylureas)
Other GLP-1 / incretin drugs

Side Effects:

Nausea / vomitingDiarrhea / constipation / bloatingTreatment discontinuation due to GI events

Limited safety

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Prior serious hypersensitivity to liraglutide or any GLP-1 receptor agonist

Drug Interactions:

Insulin and sulfonylureas
Oral medications (general)
Other GLP-1 receptor agonists

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

How they work together

Like what you see? Add these to your stack.

See how they work together through biological pathways.

Build Your Stack

Want to compare more supplements?

Loading comparison...